Aggressive breast cancer cells with mesenchymal traits such as MDA-MB-231 and Hs578T, as well as basal-like breast tumors, express high levels of SRGN, in contrast to epithelial breast cancer cells and respective luminal subtypes of breast cancer. Here, SRGN is linked to breast neoplasm.